Skip to main content
. 2021 Apr 15;11:8321. doi: 10.1038/s41598-021-87700-2

Figure 2.

Figure 2

(a) Non-transduced (NT) and LV/hu-IL-12 transduced human sarcoma lines for osteosarcoma (143B), Ewing sarcoma (A673), and rhabdomyosarcoma (RD) were plated in ultralow adherent 96-well plates. After 48 h of growth, media or NK-92mi at a 10:1 ratio were added. Supernatants were assessed by ELISA for IFN-γ. N = 12; 3 independent experiments, displayed mean ± standard deviation. (b) Non-transduced and LV/hu-IL-12 transduced human sarcoma lines were plated. 4 h later conditioned supernatant was collected and 100 µL applied to NK-92mi cells. After an additional 4 h supernatant was collected, and IFN-γ was measured by ELISA. N = 6; 2 independent experiments, displayed mean ± standard deviation. (c) NK-92mi cells were incubated in the presence or absence of anti-IL-12 antibody and 100 µL of conditioned supernatant. After 4 h supernatant was collected, and IFN-γ was measured by ELISA. N = 6; 2 independent experiments, displayed mean ± standard deviation. (d) Primary human NK cells were plated with non-transduced (NT) and LV/hu-IL-12 transduced human Ewing sarcoma (A673) at the noted E:T ratios or conditioned supernatant (100 µL) in the presence or absence of anti-IL-12 antibody. After 6 h supernatant was collected, and IFN-γ was measured by ELISA. N = 3; displayed mean ± standard deviation. * = p < 0.05, ** = p < 0.001, *** = p < 0.0001.